| Criteria | Stage B (Pre-Heart Failure) | Ray’s Disease |
|---|---|---|
| Diagnostic Approach | Based on structural heart abnormalities detected via imaging (e.g., echocardiography). | AI-powered predictions using a 12-lead EKG, independent of structural changes. |
| Predictive Certainty | Flags patients as “at risk” without a defined timeframe for progression. | Provides a clear timeframe (3–24 months) for symptom onset with high accuracy (97.5% sensitivity, 99.9% specificity). |
| Clinical Implications | General recommendations for monitoring and lifestyle modifications. | Enables targeted preventive treatments and intensive monitoring for high-risk patients. |
| Focus | Risk stratification based on structural indicators. | Proactive identification of asymptomatic patients with a near-certain risk of progression. |
- Accurate Predictions: High sensitivity (97.5%) and specificity (99.9%) ensure reliable identification of at-risk individuals.
- Non-Invasive Screening: Uses only a standard 12-lead EKG, making it accessible and cost-effective.
- Timely Interventions: Identifies patients likely to develop symptoms within a defined timeframe, enabling preventive therapies and reducing healthcare costs.
- Ease of Use: A software-only solution that integrates seamlessly with existing clinical workflows.
- Global Applicability: Effective across diverse populations, with demonstrated accuracy in both resource-rich and underserved settings.
- Comprehensive Insight: Correlates predictions with established markers like NT-proBNP and echocardiographic findings for robust validation.